2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
20
Lung Neoplasms
7
Neoplasms
5
Adenocarcinoma of Lung
5
Lymphoma, Large-Cell, Anaplastic
4
Neuroblastoma
3
Neoplasm Metastasis
3
Hematologic Neoplasms
3
Granuloma, Plasma Cell
3
Melanoma
2
Glioblastoma
2
Cholangiocarcinoma
2
Brain Neoplasms
2
Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
1
Thyroid Carcinoma, Anaplastic
1
Sarcoma
1
Rhabdomyosarcoma
1
Pancreatic Neoplasms
1
Noonan Syndrome 6
1
Non-small Cell Lung Cancer Harboring ROS1 Rearrangement
1
Lymphoma, B-Cell
1
Carcinoma, Pancreatic Ductal
1
Carcinoma
1
Adenocarcinoma Of Esophagus
1
ALK-positive Non-small Cell Lung Cancer
1
ALK-positive NSCLC
1
ALK-positive Advanced Tumors
1
Interventions
Rituximab
112
Cyclophosphamide
103
fludarabine
61
Doxorubicin
33
Vincristine
31
Etoposide
31
Prednisone
30
Lenalidomide
24
ibrutinib
22
fludarabine phosphate
21
Immunotherapy, Adoptive
19
Bendamustine Hydrochloride
19
obinutuzumab
18
Cytarabine
18
pembrolizumab
16
Magnetic Resonance Spectroscopy
16
Bortezomib
14
Specimen Handling
13
Dexamethasone
13
polatuzumab vedotin
12
CT-P10
12
venetoclax
11
Gemcitabine
11
Carboplatin
11
pirtobrutinib
10
glofitamab
10
zanubrutinib
9
Nivolumab
9
Mycophenolic Acid
9
Melphalan
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell
×
ceritinib
×
Clear all
NCT02186821
2021-04-08
SIGNATURE
Novartis
Phase 2
Terminated
47 enrolled
13 charts